Immunogen Stock News

ImmunoGen, Inc. (NASDAQ:IMGN) Investment analysts at Jefferies Financial Group dropped their FY2022 earnings estimates for ImmunoGen in a report released on Tuesday, November 30th. Jefferies Financial Group analyst K. Shi now expects that the biotechnology company will post earnings per share of ($1.40) for the year, down from their previous forecast of ($1.36). Jefferies [] The post FY2022 Earnings Estimate for ImmunoGen, Inc. Issued By Jefferies Financial Group (NASDAQ:IMGN) appeared first on ETF Daily News .

ImmunoGen announced positive results from the phase 3 SORAYA trial using mirvetuximab for ovarian cancer patients, meeting both the primary and secondary endpoints. A pivotal confirmatory study using

ImmunoGen, Inc. (NASDAQ:IMGN) Analysts at Jefferies Financial Group dropped their FY2022 earnings per share estimates for shares of ImmunoGen in a research note issued to investors on Tuesday, November 30th. Jefferies Financial Group analyst K. Shi now forecasts that the biotechnology company will post earnings per share of ($1.40) for the year, down from []

ImmunoGen, Inc. (NASDAQ:IMGN) Stock analysts at Piper Sandler lifted their Q1 2022 earnings per share estimates for shares of ImmunoGen in a research report issued on Tuesday, November 30th. Piper Sandler analyst J. Catanzaro now forecasts that the biotechnology company will post earnings per share of ($0.26) for the quarter, up from their prior []

ImmunoGen (NASDAQ:IMGN) had its price objective lifted by Royal Bank of Canada from $8.00 to $9.00 in a research note issued to investors on Tuesday, The Fly reports. They currently have an outperform rating on the biotechnology companys stock. Several other equities research analysts have also commented on IMGN. SVB Leerink reduced their price target []

ImmunoGen, Inc. (NASDAQ:IMGN)s stock price was up 6.8% on Thursday . The company traded as high as $7.27 and last traded at $7.23. Approximately 701,310 shares traded hands during trading, a decline of 70% from the average daily volume of 2,306,286 shares. The stock had previously closed at $6.77. A number of equities analysts have []

Royal Bank of Canada decreased its holdings in ImmunoGen, Inc. (NASDAQ:IMGN) by 25.9% in the second quarter, HoldingsChannel reports. The institutional investor owned 132,749 shares of the biotechnology companys stock after selling 46,412 shares during the period. Royal Bank of Canadas holdings in ImmunoGen were worth $874,000 at the end of the most recent reporting []

Investor sentiment has turned against this promising cell therapy company.

The biotech is continuing to surge after after a late-stage win in treatment for advanced ovarian cancer.

Why these hot penny stocks exploded today The post These Penny Stocks Exploded Today, Are They On Your List? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.

Companies in the news are: CHS, CTRN, IMGN, ERYP

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir The Food and Drug Adminis